Leerink Partnrs Analysts Decrease Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW) – Stock analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for Edwards Lifesciences in a report released on Wednesday, February 12th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will post earnings per share of $2.41 for the year, down from their previous forecast of $2.43. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2026 earnings at $2.76 EPS and FY2027 earnings at $3.23 EPS.

Other equities research analysts also recently issued research reports about the company. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday. Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday. Piper Sandler upped their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Barclays upped their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $76.23 on Thursday. The company’s 50 day moving average price is $72.58 and its two-hundred day moving average price is $69.41. The firm has a market capitalization of $44.96 billion, a P/E ratio of 11.00, a P/E/G ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently bought and sold shares of the company. Harbor Capital Advisors Inc. increased its position in shares of Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after purchasing an additional 273 shares in the last quarter. Nordea Investment Management AB increased its position in Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after buying an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its stake in Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after buying an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $3,702,000. Finally, Avanza Fonder AB purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $4,845,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.